Insider Selling: NeuroPace, Inc. (NASDAQ:NPCE) Major Shareholder Sells 24,609 Shares of Stock

NeuroPace, Inc. (NASDAQ:NPCE - Get Free Report) major shareholder Orbimed Advisors Llc sold 24,609 shares of the firm's stock in a transaction that occurred on Monday, April 22nd. The stock was sold at an average price of $14.05, for a total transaction of $345,756.45. Following the sale, the insider now directly owns 3,459,113 shares in the company, valued at approximately $48,600,537.65. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Large shareholders that own at least 10% of a company's stock are required to disclose their transactions with the SEC.

Orbimed Advisors Llc also recently made the following trade(s):

• On Thursday, April 18th, Orbimed Advisors Llc sold 2,623 shares of NeuroPace stock. The shares were sold at an average price of $14.06, for a total transaction of $36,879.38.
• On Tuesday, April 16th, Orbimed Advisors Llc sold 14,069 shares of NeuroPace stock. The shares were sold at an average price of $14.01, for a total transaction of $197,106.69.
• On Thursday, April 11th, Orbimed Advisors Llc sold 461,899 shares of NeuroPace stock. The shares were sold at an average price of $14.49, for a total transaction of $6,692,916.51.

NeuroPace Price Performance

Shares of NASDAQ NPCE traded up $0.01 during trading on Tuesday, hitting $14.01. 152,876 shares of the company were exchanged, compared to its average volume of 107,182. The company has a market cap of $368.18 million, a price-to-earnings ratio of -10.95 and a beta of 2.09. NeuroPace, Inc. has a 1 year low of $3.80 and a 1 year high of $18.15. The firm's fifty day moving average price is $14.41 and its 200 day moving average price is $11.52. The company has a debt-to-equity ratio of 2.76, a current ratio of 5.71 and a quick ratio of 5.02.

NeuroPace (NASDAQ:NPCE - Get Free Report) last issued its earnings results on Tuesday, March 5th. The company reported ($0.23) EPS for the quarter, topping the consensus estimate of ($0.33) by $0.10. The company had revenue of $18.01 million for the quarter, compared to analyst estimates of $17.74 million. NeuroPace had a negative net margin of 50.38% and a negative return on equity of 153.76%. On average, sell-side analysts expect that NeuroPace, Inc. will post -1.14 earnings per share for the current fiscal year.

Institutional Investors Weigh In On NeuroPace

Several institutional investors have recently made changes to their positions in NPCE. Citigroup Inc. purchased a new stake in shares of NeuroPace in the 3rd quarter worth about $29,000. Barclays PLC raised its stake in NeuroPace by 9,085.6% in the 3rd quarter. Barclays PLC now owns 10,839 shares of the company's stock valued at $105,000 after purchasing an additional 10,721 shares during the last quarter. EAM Investors LLC acquired a new position in NeuroPace in the 3rd quarter valued at about $1,378,000. Finally, Kent Lake Capital LLC raised its stake in NeuroPace by 285.0% in the 3rd quarter. Kent Lake Capital LLC now owns 574,417 shares of the company's stock valued at $5,589,000 after purchasing an additional 425,212 shares during the last quarter. 78.83% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities analysts have recently commented on NPCE shares. Morgan Stanley lifted their target price on shares of NeuroPace from $9.00 to $13.00 and gave the company an "equal weight" rating in a report on Wednesday, March 6th. Lake Street Capital reaffirmed a "buy" rating and issued a $12.00 target price on shares of NeuroPace in a report on Wednesday, December 27th. Cantor Fitzgerald lifted their target price on shares of NeuroPace from $16.00 to $18.00 and gave the company an "overweight" rating in a report on Wednesday, March 6th. Leerink Partnrs reiterated an "outperform" rating on shares of NeuroPace in a research report on Tuesday, January 30th. Finally, SVB Leerink initiated coverage on shares of NeuroPace in a research report on Tuesday, January 30th. They issued an "outperform" rating and a $22.00 price objective on the stock. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $15.67.

About NeuroPace

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.